Thermo Fisher Scientific Commences Tender Offer for All Outstanding Common Shares and ADSs of Olink
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, and Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions, today announced that Thermo Fisher has commenced the previously announced tender offer (the “Offer") through a direct, wholly owned subsidiary of Thermo Fisher (the “Buyer”) to acquire all of the outstanding common shares and all of the outstanding American Depositary Shares (“ADSs”) of Olink for $26.00 per common share and per ADS, in cash.
The Offer and withdrawal rights will expire at 6:00 p.m., New York time, on November 30, 2023, unless the Offer is extended or earlier terminated. The Offer is subject to customary closing conditions, including receipt of applicable regulatory approvals and a minimum tender condition. The conditions to the Offer are set forth in their entirety in the Offer to Purchase, the ADS letter of transmittal and the acceptance form for shares (including the instructions attached thereto), which Thermo Fisher has filed today with the U.S. Securities and Exchange Commission (the “SEC”).
After careful consideration, the board of directors of Olink has recommended that Olink shareholders accept the Offer and tender their common shares and ADSs to the Buyer pursuant to the Offer.
As part of the transaction, Summa Equity AB, Olink’s largest shareholder, and additional Olink shareholders and management, in aggregate holding approximately 66% of Olink’s shares, have entered into support agreements agreeing to tender into the tender offer.
Requests for copies of the Offer to Purchase, the ADS letter of transmittal and the acceptance form for shares (including the instructions attached thereto) and other tender offer materials may be directed to the call service of Georgeson LLC at +1-866-821-2550 (U.S. toll-free), +1-781-222-0033 (outside U.S. & Canada) or +46-846-007-389 (Sweden), or via email at firstname.lastname@example.org. A copy of these documents may be obtained at the website maintained by the SEC at www.sec.gov.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Olink Holding AB (publ) (Nasdaq:OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
This press release contains forward-looking statements that involve a number of risks and uncertainties. Words such as “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements, but other statements that are not historical facts may also be deemed to be forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the COVID-19 pandemic, the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, including the proposed acquisition, may not materialize as expected; the proposed acquisition not being timely completed, if completed at all; regulatory approvals required for the transaction not being timely obtained, if obtained at all, or being obtained subject to conditions; prior to the completion of the transaction, Olink’s business experiencing disruptions due to transaction-related uncertainty or other factors making it more difficult to maintain relationships with employees, customers, licensees, other business partners or governmental entities; difficulty retaining key employees; the outcome of any legal proceedings related to the proposed acquisition; and the parties being unable to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in Thermo Fisher’s Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are on file with the U.S. Securities and Exchange Commission (“SEC”) and available in the “Investors” section of Thermo Fisher’s website, ir.thermofisher.com, under the heading “SEC Filings”, and in any subsequent documents Thermo Fisher files or furnishes with the SEC, and in Olink’s Annual Report on Form 20-F and subsequent interim reports on Form 6-K, which are on file with the SEC and available in the “Investor Relations” section of Olink’s website, https://investors.olink.com/investor-relations, under the heading “SEC Filings”, and in any subsequent documents Olink files or furnishes with the SEC. While Thermo Fisher or Olink may elect to update forward-looking statements at some point in the future, Thermo Fisher and Olink specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing either Thermo Fisher’s or Olink’s views as of any date subsequent to today.
Additional Information and Where to Find It
This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any common shares or American Depositary Shares of Olink or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or the Buyer has filed with the SEC. The terms and conditions of the tender offer are published in, and the offer to purchase common shares and American Depositary Shares of Olink is made only pursuant to, the offer document and related offer materials prepared by Thermo Fisher and the Buyer and is filed with the SEC in a tender offer statement on Schedule TO. In addition, Olink has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer.
THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A ADS LETTER OF TRANSMITTAL, ACCEPTANCE FORM FOR SHARES AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AS THEY MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION. INVESTORS AND SHAREHOLDERS OF OLINK ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY, AND NOT THIS DOCUMENT, GOVERN THE TERMS AND CONDITIONS OF THE TENDER OFFER, AND BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR COMMON SHARES AND AMERICAN DEPOSITARY SHARES.
The tender offer materials, including the offer to purchase, the related ADS letter of transmittal and acceptance form for shares and certain other tender offer documents, and the solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or Olink, may be obtained free of charge at the SEC's website at www.sec.gov, at Olink’s website https://investors.olink.com/investor-relations, at Thermo Fisher's website at www.thermofisher.com or by contacting Thermo Fisher's investor relations department at 781-622-1111. In addition, Thermo Fisher's tender offer statement and other documents it will file with the SEC will be available at https://ir.thermofisher.com/investors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Investor Contact Information:
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VIOOH Shares Industry-first Carbon Emissions Measurement Hitting 18% Below Benchmark11.12.2023 09:00:00 CET | Press release
Today, VIOOH, the leading premium global digital out of (DOOH) home supply-side platform, announced a partnership with the Carbon Intelligence Platform, Cedara, a supporter of Ad Net Zero. In an industry first for a programmatic DOOH (prDOOH) player, VIOOH has shared publicly its impression intensity carbon emissions (grams CO2e) per ad impression for 2022, which is 18% below the programmatic open web benchmark. Based on Cedara’s measurement, VIOOH generated 0.28 grams CO2e per ad impression in 2022, well below the Cedara ad platform benchmark of 0.34, which is based on programmatic open web vendor data. VIOOH worked closely with Cedara on a comprehensive greenhouse gas (GHG) inventory assessment across its operations, including programmatic media activity, which contributes the majority of Scope 3 emissions. As part of its measurement process, Cedara not only analysed data sets from business operations, but also activity data from media delivery, data centres, and media owners, amongs
Hexadrone Starts C5 and C6 Drone Type Examination After Successful GAP Analysis of The TUNDRA 2’ Specification by Notified Body11.12.2023 08:30:00 CET | Press release
Hexadrone SAS, A French Modular UAV’s Manufacturer Created in 2014 has successfully completed GAP Analysis for The Tundra 2 in its Urban and Endurance versions versus DR EU 2019/945 with intension for Class Identification Label C5 and C6. With the achievement of this milestone, the certification process for both Urban and Endurance Version have been now formally triggered by Hexadrone to be performed by the notified body NavCert GmbH. The Tundra 2 is bringing on the market a key differentiator by providing extreme modularity on UAVs, integrating unlimited type of payloads used in various sectors like, Surveillance, Geospatial, Agriculture, Oil and gas, Military, Homeland security, Rescue and much more. “Through an in-depth analysis based on European Union (EU) Regulation 2019/945, we have ensured that the specifications of the Tundra 2 as well as our user manuals fully meet the current requirements. This compliance will ensure that the TUNDRA 2 users will be able to fly in European air
VINSSEN Co., Ltd. Successfully Supplies Hydrogen Fuel Cell for Industry Project in Singapore11.12.2023 08:00:00 CET | Press release
VINSSEN Co., Ltd. (CEO Chil-Han Lee), a company specializing in the production of electric and hydrogen hybrid propulsion systems, has successfully tested and delivered a hydrogen fuel cell system for a trial project involving several key industry partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210481971/en/ Hydrogen fuel cell power generation equipment is undergoing inspection before delivery (Photo: VINSSEN Co., Ltd.) VINSSEN is collaborating with Shell Singapore Pte. Ltd. (Shell) as the project sponsor, Seatrium Limited as the project developer, Penguin International Limited as the owner and operator of the vessel, and Air Liquide Singapore Private Limited as the hydrogen supplier. This project is a pilot to test the use of hydrogen fuel cells in maritime applications, marking the first step in confirming feasibility of hydrogen as a marine fuel. The hydrogen fuel cell system has been delivered from Korea and
New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation11.12.2023 08:00:00 CET | Press release
Masimo (NASDAQ: MASI) today announced the findings of a retrospective study published in the Journal of Anesthesia in which Dr. Yu Jeong Bang and colleagues at the Samsung Medical Center, Sungkyunkwan University School of Medicine, in Seoul, South Korea, investigated the association of Masimo ORi™ and the arterial partial pressure of oxygen (PaO2) in 554 patients who underwent non-cardiac thoracic surgery during one-lung ventilation (OLV), making this study the largest to date on ORi. The researchers found that ORi values “were significantly correlated with PaO2 measured simultaneously” and that ORi “could provide useful information on arterial oxygenation even during one-lung ventilation.”1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210873994/en/ Masimo Root® with ORi™ (Photo: Business Wire) Noninvasive, continuous Masimo ORi provides continuous, real-time insight into the oxygenation of hemoglobin in the moderate hy
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement11.12.2023 07:00:00 CET | Press release
Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210383233/en/ The deal provides Ferring with exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration. The financial details of this deal are undisclosed. “This agreement is the latest in Ferring’s long term mission to maximise the therapeutic potential of the gut microbiome for the benefit of patients. PharmaBiome’s unique technology enables identification and manufacturing of defined consortium live microbiome biotherapeutics that could reverse microbiome dysbiosis linked to disease,” said Carl Bilbo, Senior Vice President, Micr